Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis

Arthritis Care and Research

Volumn 66, Issue 7, 2014, Pages 1016-1026

  Hua, Charlotte ^a   Barnetche, Thomas ^b   Combe, Bernard ^a   Morel, Jacques ^a  

^a UNIV MONTPELLIER   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; METHOTREXATE; PNEUMOCOCCUS VACCINE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIBODY TITER; DRUG EFFICACY; HUMAN; HUMORAL IMMUNITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SEROTYPE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; DOWN-REGULATION; HUMANS; IMMUNITY, HUMORAL; INFLUENZA VACCINES; METHOTREXATE; PNEUMOCOCCAL VACCINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903447241     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22246     Document Type: Review

References (41)

1. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE,. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
2. Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-22.
3. Pneumococcal vaccines. URL: http://archives.who.int/vaccines/en/ pneumococcus.shtml.
4. Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6121a3.htm.
5. Centers for Disease Control and Prevention (CDC). PCV13 (pneumococcal conjugate) vaccine. URL: http://www.cdc.gov/vaccines/vpd-vac/pneumo/vac-PCV13- adults.htm.
6. Gluck T,. Vaccinate your immunocompromised patients! Rheumatology (Oxford) 2006; 45: 9-10.
7. Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49: 1815-27.
8. Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011; 63: 1062-7.
9. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34: 147-53.
10. Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994; 21: 1203-6.
11. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. URL: http://www.ohri.ca/programs//clinical-epidemiology/ oxford.htm.
12. Siegrist CA,. Vaccine immunology. In:, Plotkin S, Orenstein W, Offit P, editors. Vaccines. 6th ed. Philadelphia: W.B. Saunders Company; 2012. p. 17-36.
13. Committee for Proprietary Medicinal Products (CPMC). Concept paper on the revision of the CPMP/BWP note for guidance on harmonization of requirements for influenza vaccines. 2001. CPMP/EPW/1045/01.
14. WHO Expert Committee on Biological Standardization. WHO technical report studies: fifty-fourth report. Geneva: World Health Organization; 2005.
15. Go ES, Ballas ZK,. Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J Allergy Clin Immunol 1996; 98: 205-15.
16. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers. Ann Rheum Dis 2006; 65: 191-4.
17. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P,. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007; 46: 608-11.
18. Kaine JL, Kivitz AJ, Birbara C, Luo AY,. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 272-9.
19. Kivitz A, Schechtman J, Texter M, Fichtner A, Chartash E,. Assessment of immune responses to pneumococcal and influenza vaccines in patients with rheumatoid arthritis receiving certolizumab pegol [abstract]. Arthritis Rheum 2011; 63 Suppl: S488.
20. Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y, et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2007; 17: 531-3.
21. Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67: 937-41.
22. Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011; 29: 1643-8.
23. Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P,. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 106-11.
24. Kapetanovic MC, Roseman C, Jonsson G, Truedsson L, Saxne T, Geborek P,. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011; 63: 3723-32.
25. Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL,. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007; 34: 952-7.
26. Bingham CO III, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62: 64-74.
27. Kapetanovic MC, Roseman C, Jonsson G, Truedsson LT, Saxne TV, Geborek P,. Rituximab and methotrexate but not TNF-blockers are associated with impaired antibody response following pneumococcal vaccination using 7-valent conjugate vaccine (Prevenar®) in patients with established rheumatoid arthritis [abstract]. Arthritis Rheum 2011; 63 Suppl: S148.
28. Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010; 39: 442-7.
29. Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open- label, parallel-cohort, single-center study. Arthritis Rheum 2011; 63: 1486-96.
30. Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis 2011; 70: 2144-7.
31. Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease: a prospective controlled vaccination study. Rheumatology (Oxford) 2012; 51: 695-700.
32. Van Assen S, Holvast A, Benne CA, Posthumus MD, Van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62: 75-81.
33. Gelinck LB, Van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, Van Hogezand RA, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 713-6.
34. Kapetanovic MC, Roseman C, Jonsson G, Truedsson L,. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol 2011; 30: 1555-61.
35. Hayashi M, Kojima T, Ishiguro N, Kobayakawa T, Kanamono T,. Seroresponse rates after influenza vaccination in rheumatoid arthritis patients treated with biological agents during the 2011-2012 flu season [abstract]. Arthritis Rheum 2012; 64 Suppl: S1038-9.
36. Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65: 476-80.
37. Tsuru T, Terao K, Suzaki M, Nakashima H, Amamoto T, Akiyama A, et al. Immune response to pneumococcal vaccine in patients with rheumatoid arthritis under IL-6 receptor inhibition therapy with tocilizumab [abstract]. Arthritis Rheum 2007; 56 Suppl: S423.
38. Bingham CO III, Rizzo WC, Klearman M, Hassanali A, Upmanyu R, Kivitz AJ,. Preliminary results from a controlled study assessing the humoral immune response to vaccines in rheumatoid arthritis patients treated with tocilizumab [abstract]. Arthritis Rheum 2012; 64 Suppl: S151.
39. Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K,. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 2012; 71: 2006-10.
40. Lesprit P, Pedrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21: 2425-34.
41. De Roux A, Schmole-Thoma B, Schmoele-Thoma B, Siber GR, Hackell JG, Kuhnke A, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46: 1015-23.